Figure 5: Treatment with UNC2025 inhibits tumor growth in a BRAF^mt patient-derived melanoma xenograft model alone and in combination with vemurafenib.

A xenograft-passaged BRAF^mt melanoma patient sample (MB2117) was transplanted into nude mice, and mice with established tumors were treated with 40 or 50 mg/kg UNC2025 twice daily (BID), 40 mg/kg vemurafenib once daily, or equivalent doses of UNC2025 and vemurafenib in combination, or vehicle. Tumor volumes were measures at intervals. A) n=6, * p < 0.05, ** p < 0.01, *** p < 0.001, two-way ANOVA B) n=10–13, ** p <0.01 versus vehicle, *** p < 0.001 versus vehicle, # p <0.05 versus vemurafenib monotherapy, two-way ANOVA. Asterisks denote comparison between vehicle and combination treatment. Data shown are representative of two independent experiments.